Filter Results:
(624)
Show Results For
- All HBS Web
(624)
- People (2)
- News (57)
- Research (449)
- Events (2)
- Multimedia (8)
- Faculty Publications (395)
Show Results For
- All HBS Web
(624)
- People (2)
- News (57)
- Research (449)
- Events (2)
- Multimedia (8)
- Faculty Publications (395)
- February 2024 (Revised March 2025)
- Case
Moving Science: The Rowland Institute at Harvard
By: Maria P. Roche
Set in 2022, this case describes the considerations involved in organizing the physical relocation of the Rowland Institute at Harvard (RIH), a research institute established in 1980 by Edwin H. Land, the founder of the Polaroid Corporation, for the advancement of... View Details
Keywords: Optics; Engineering; Higher Education; Strategy; Science; Buildings and Facilities; Research and Development; Biotechnology Industry; Biotechnology Industry
Roche, Maria P. "Moving Science: The Rowland Institute at Harvard." Harvard Business School Case 724-441, February 2024. (Revised March 2025.)
- January 2014 (Revised June 2014)
- Supplement
23andMe: Genetic Testing for Consumers (B)
By: John A. Quelch and Margaret L. Rodriguez
Following the FDA's letter in November 2013, which ordered 23andMe to cease sales of its DNA test kits, observers wondered how co-founder and CEO, Anne Wojcicki, would guide the company in the presence of uncertainty. View Details
Keywords: Risk and Uncertainty; Genetics; Crisis Management; Health Care and Treatment; Product Development; Business and Government Relations; Biotechnology Industry; Biotechnology Industry; United States
Quelch, John A., and Margaret L. Rodriguez. "23andMe: Genetic Testing for Consumers (B)." Harvard Business School Supplement 514-095, January 2014. (Revised June 2014.)
- April 1995 (Revised April 1999)
- Teaching Note
Aberlyn Capital Management TN
By: Josh Lerner
Teaching Note for (9-294-083). View Details
- March 2025 (Revised April 2025)
- Teaching Note
Moving Science: The Rowland Institute at Harvard
By: Maria Roche
Teaching Note for HBS Case No. 724-441. View Details
- 12 Mar 2013
- First Look
First Look: March 12
A. Arnaout Publication:Nature Biotechnology Abstract Advances in biotechnology have fueled the generation of unprecedented quantities of data across the life sciences. However, finding analysts who can... View Details
Keywords: Sean Silverthorne
- 15 Feb 2000
- Research & Ideas
The Right Connections
of IPO Team Ties on Investment Bank Affiliation and IPO Success," which examines how individuals' affiliations can affect the formation of alliances at the firm level. To that end, the researchers pinpointed the biotechnology... View Details
Keywords: by Judith A. Ross
- 01 Jun 2005
- News
Marked Managers
assignments. In the 1980s, biotechnology was a fledgling field. The scientists who were making breakthroughs and their venture capitalists needed businesspeople who were entrepreneurial and who could piece together an organization without... View Details
- 01 Dec 1996
- News
New Releases
a competitive factor. In a three-year study of pharmaceutical and biotechnology firms, Pisano shows that the development of distinctive and superior process technologies can lower costs, improve quality, and increase flexibility. He... View Details
- 01 Dec 1996
- News
Entrepreneurship at HBS
direct marketing, consumer products, and consulting. Following Professor Georges F. Doriot's lead, our graduates have had a major impact on the venture capital industry, which in turn financed a revolution in semiconductors, personal computers, communications, and... View Details
- Profile
Terrance McGuire
and entrepreneur, during which time they have collaborated on a long list of successful biotechnology startups. “Bob Langer is passionate about improving peoples' lives,” McGuire said. “He was one of the early... View Details
- 26 Jul 2016
- Working Paper Summaries
The Impact of the Entry of Biosimilars: Evidence from Europe
- 21 Apr 2014
- Research & Ideas
Bio-Piracy: When Western Firms Usurp Eastern Medicine
In May 1995, two scientists at the University of Mississippi were granted an American patent for the use of turmeric to treat flesh wounds. Soon thereafter, an Indian research organization won a lawsuit challenging the novelty of the patent. As it turned out, Indians... View Details
- 18 Sep 2019
- Working Paper Summaries
Female Inventors and Inventions
- Research Summary
Overview
I am interested in the individual experience of learning in organizational settings, particularly how employees learn to learn from the challenging work they do.
I am currently researching the role of reflection for raising awareness of learning opportunities that... View Details
- Article
Internal Deadlines, Drug Approvals, and Safety Problems
By: Lauren Cohen, Umit Gurun and Danielle Li
Absent explicit quotas, incentives, reporting, or fiscal year-end motives, drug approvals around the world surge in December, at month-ends, and before respective major national holidays. Drugs approved before these informal deadlines are associated with significantly... View Details
Keywords: Health; Economics; Government and Politics; Innovation and Invention; Research; Science; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry
Cohen, Lauren, Umit Gurun, and Danielle Li. "Internal Deadlines, Drug Approvals, and Safety Problems." American Economic Review: Insights 3, no. 1 (March 2021): 67–82.
- 1 Aug 2010
- Conference Presentation
Lords of the harvest: Symbolic signaling and regulatory approval of genetically modified organisms in the nascent U.S. agriculture-biotechnology sector
By: Shon R. Hiatt and Sangchan Park
Keywords: Science; Information Technology; Governing Rules, Regulations, and Reforms; Agribusiness; Biotechnology Industry; Biotechnology Industry; United States
Hiatt, Shon R., and Sangchan Park. "Lords of the harvest: Symbolic signaling and regulatory approval of genetically modified organisms in the nascent U.S. agriculture-biotechnology sector." Paper presented at the Academy of Management Annual Meeting, Montreal, Canada, August 01, 2010.
- December 2008 (Revised January 2011)
- Case
Arcadia Biosciences: Seeds of Change
By: Arthur A. Daemmrich, Forest L. Reinhardt and Mary Louise Shelman
Arcadia Biosciences is an entrepreneurial California agricultural biotech company seeking to earn carbon credits by modifying commodity crops for use in China and India. Eric Rey, Arcadia's CEO, faced a strategic inflection point in early September 2008. The company... View Details
Keywords: Business Startups; Entrepreneurship; Growth and Development Strategy; Environmental Sustainability; Science-Based Business; Climate Change; Agriculture and Agribusiness Industry; Biotechnology Industry; China; India; California
Daemmrich, Arthur A., Forest L. Reinhardt, and Mary Louise Shelman. "Arcadia Biosciences: Seeds of Change." Harvard Business School Case 709-019, December 2008. (Revised January 2011.)
- December 2005 (Revised July 2006)
- Case
Bunge: Poised for Growth
By: David E. Bell and Mary L. Shelman
As CEO of the world's largest oilseed processor, Alberto Weisser of Bunge must not only decide how quickly to expand in fast-growing markets of Eastern Europe and Asia, but also how best to leverage the firm's global footprint and leadership position. The firm is... View Details
Keywords: Customer Focus and Relationships; Trade; Global Strategy; Leadership; Growth Management; Management Style; Demand and Consumers; Supply Chain; Integration; Technology; Biotechnology Industry; Biotechnology Industry; Asia; Europe
Bell, David E., and Mary L. Shelman. "Bunge: Poised for Growth." Harvard Business School Case 506-036, December 2005. (Revised July 2006.)
- 22 Sep 2020
- Research & Ideas
Recessions Push Some Entrepreneurs to Launch Too Soon
an associate professor at University of Lausanne, studied 3,025 US founders from 2005 to 2012 and their 1,747 startups in the biotechnology and medical device sectors during previous economic downturns. Their research was conducted before... View Details
Keywords: by Sean Silverthorne
- 07 Apr 2003
- Research & Ideas
Three Steps for Crisis Prevention
challenges, not on the hard work of winning hearts and minds, Shapiro ultimately lost his company. He was forced to sell Monsanto to Pharmacia-Upjohn, which bought it for its pharmaceutical division, valuing the agricultural biotechnology... View Details
Keywords: by Michael D. Watkins & Max H. Bazerman